The Company’s cash position as of December 31, 2023, was $9.4 million compared to $12.1 million as of December 31, 2022. The Company believes that its cash position, including the proceeds of the $51 million private placement completed on February 28, 2024, will be sufficient to fund operations through the release of top-line data from its first Phase 3 study of cadisegliatin.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTVT:
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
- vTv Therapeutics Enhances Investor Communication with Update
- vTv Therapeutics announces FDA submission for Phase 3 study of cadisegliatin
- Biotech Alert: Searches spiking for these stocks today
- vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference